Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma (RCC).

Considering recent data with combinations such as axitinib (Inlyta) plus avelumab (Bavencio), and lenvatinib (Lenvima) plus pembrolizumab (Keytruda), McGregor believes that combinations in RCC will be moving toward the frontline setting.

Multiple trials are ongoing to determine what that combination will be.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Dana-Farber Cancer Institute

Cancer Centers

Partner

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.
 

Dr. McGregor Discusses the Future of Treatment for RCC